Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)

Summary

This Phase 2, randomized, double-blind, placebo-controlled, multicenter, dose-ranging study will compare the efficacy, safety, and tolerability of cicletanine hydrochloride (HCl) to placebo in subjects with PAH. Study drug will be administered alone, or on the background of stable PAH therapy. The study will consist of 3 periods: a screening period, a 12-week placebo-controlled treatment period, and a long-term, blinded extension period.

Timeline

Start

2009-01

Primary completion

2011-10

Completion

2012-03

Drugs

Indications